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Abstract: The problem of endemic malaria continues unabated globally. Ma-
laria affects 40 % of the global population, causing an estimated annual mor-
tality of 1.5–2.7 million people. The World Health Organization (WHO) esti-
mates that 90 % of these deaths occur in sub-Saharan Africa among infants 
under the age of five. While a vaccine against malaria continues to be elusive, 
chemotherapy remains the most viable alternative towards treatment of the dis-
ease. During last years, the situation has become urgent in many ways, but 
mainly because of the development of chloroquine-resistant (CQR) strains of 
Plasmodium falciparum (Pf). The discovery that artemisinin (ART, 1), an ac-
tive principle of Artemisia annua L., expresses a significant antimalarial acti-
vity, especially against CQR strains, opened new approaches for combating 
malaria. Since the early 1980s, hundreds of semi-synthetic and synthetic per-
oxides have been developed and tested for their antimalarial activity, the results 
of which were extensively reviewed. In addition, in therapeutic practice, there 
is no reported case of drug resistance to these antimalarial peroxides. This re-
view summarizes recent achievements in the area of peroxide drug develop-
ment for malaria chemotherapy. 
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1. INTRODUCTION 
The problem of endemic malaria continues unabated globally. Malaria af-
fects 40 % of the global population, causing an estimated annual mortality of 
1.5–2.7 million people.1 The World Health Organization (WHO) estimates that 
90 % of these deaths occur in sub-Saharan Africa among infants under the age of 
five.2 While a vaccine against malaria continues to be elusive,3 chemotherapy re-
mains the most viable alternative towards treatment of the disease. During the 
last years, the situation has become urgent in many ways, but mainly because the 
malaria parasite has developed multiple drug resistance to clinically established 
drugs (Fig. 1). This resistance is most serious with chloroquine (CQ), the most 
widely employed and cheapest drug used to treat malaria, and CQ-resistant 
(CQR) strains of Plasmodium falciparum (Pf) – Indochina W2, Brazil IEC-306, 
FCR3 and K1. The problem of combating malaria is even more complex because 
of the contemporary development of resistance of the mosquito vector to cur-
rently employed insecticides. 
 
Fig. 1. Antimalarial drugs against which the malaria parasite has developed resistance. 
The discovery that artemisinin (ART, 1), an active principle of Artemisia an-
nua L., expresses a significant antimalarial activity, especially against CQ-re-
sistant (CQR) strains,4 opened new approaches for combating malaria. Since the 
early 80s, hundreds of semi-synthetic and synthetic peroxides have been deve-
loped and tested for their antimalarial activity, the results of which were exten-
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sively reviewed.5 In addition, in therapeutic practice, there is no reported case of 
drug resistance to these antimalarial peroxides. The only evidence for in vitro 
resistance was found in French Guiana where certain ART derivatives were used 
in uncontrolled and illegal self-medication.6 
This review summarizes recent achievements in the area of peroxide drug 
development for malaria chemotherapy. 
2. THE LIFE CYCLE OF THE MALARIA PARASITE 
Protozoa of the genus Plasmodium cause malaria. Four species of Plasmo-
dium are responsible for the disease in humans: P. falciparum, P. malaria, P. 
ovale and P. vivax. Of these, P. falciparum may cause the condition known as 
cerebral malaria, which is responsible for the majority of fatal outcomes. 
The pathogenesis7 and life cycle of the malaria parasite are complex,8 con-
sisting of two stages: a sexual stage (sporogony), which occurs within the mos-
quito, and an asexual stage (schizogony), which occurs in the host.5c,9 The illness 
is started when an infected female mosquito of the genus Anopheles feeds on the 
blood of an uninfected vertebrate host. Mosquitoes inject parasites (sporozoites) 
into the subcutaneous tissue, less-frequently directly into the bloodstream. In less 
than 1 hour, the sporozoites travel to the liver, invade the hepatocites and under-
go exoerythrocitic schizogony. After some time, depending on the plasmodium 
species, the schizonts are transformed into merozoites, which after release into 
the blood stream invade erythrocytes. After significant reorganization of the 
membrane proteins of an occupied erythrocyte,8e the merozoites undergo ery-
throcytic schizogony, which comprises young rings (12 h after erythrocyte infec-
tion), mature rings (18 h), early trophozoites (24 h), mature trophozoites (30 h), 
early schizonts (36 h) and mature schizonts (42 h). At the end of erythrocytic 
schizogony, the parasites return into the merozoite form but enormously multi-
plied causing splattering of the erythrocyte. The released merozoites invade new 
red blood cells and start a new erythrocytic schizogony cycle. Erythrocytic schi-
zogony occurs every 2–3 days, depending on the plasmodium species. Each cycle 
is accompanied by typical malaria symptoms, such as fever, chills, headache and 
exhausttion. After several cycles, some of the merozoites undergo sexual deve-
lopment and are transformed into gametocytes. 
The gametocytes remain in the erythrocytes and are consumed by an ano-
pheles mosquito. In the mosquito, female and male gametocytes join and form 
zygote. Within 18 to 24 h, the zygote transforms into a slowly motile ookinete. 
Between 7 and 15 days, depending on the plasmodium species and the ambient 
temperature, a single oocyst forms more than 10,000 sporozoites. The motile spo-
rozoites migrate into the salivary glands and accumulate in the acinar cells. When 
infected, the mosquito bites a susceptible vertebrate host; a new parasite cycle 
commences. The length of the P. falciparum life cycle is presented in Table I. 
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TABLE I. Length of the various stages of the life cycle of P. falciparum 
Stage Definition Duration 
1 Ookinete formation 24 to 48 h 
2 Oocyst maturation 9 days 
Invasion of salivary glands (1+2) 10 days 
3 Circulation of sporozoites in the blood stream 1 h max. 
4 Hepatic schizogony 6 days 
5 Erythrocytic schizogony 48 h 
6 Gametocytogony 10 days 
Complete cycle (1 to 6) 27 days 
The malaria parasite has a limited capacity for de novo amino acid synthesis 
and its survival is dependent on haemoglobin proteolysis. Parasite digests haemo-
globin in the food vacuole (FV), supplies itself with amino acids necessary for 
nutrition and liberates free haem (Fe(II)PPIX), which is subsequently oxidized to 
haematin (Fe(III)PPIX). Free haematin can damage cellular metabolism by inhi-
biting enzymes, by peroxidation of membranes, and by producing oxygen radi-
cals in the acidic environment of the FV.10 In order to protect itself, the parasite 
eliminates haematin by polymerizing it into hemozoin. Hemozoin is a non-cova-
lent aggregate of several units of haematin linked via coordinate bonds formed 
between Fe(III) of one haematin and the carboxylate side chain of the adjacent 
one.11 Hemozoin is insoluble, and it is accumulated in the lymphatic tissue, liver, 
bone marrow and the brain. It was found that haem [Fe(II)PPIX] can not polyme-
rize to hemozoin and is an effective inhibitor of Fe(III)PPIX polymerization, 
even better than CQ.12 
3. ARTEMISININ AND ITS DERIVATIVES 
The herb Artemisia annua L. has been used in Chinese traditional medicine 
for centuries. The usage of plants extracts for the treatment of malaria fever is 
well documented.5a The active ingredient of the potion was identified as artemi-
sinin 1 (ART, qinghaosu – QHS, Fig. 2), a sesquiterpene lactone with an endope-
roxide function.4 The very same compound was also isolated by the Belgrade 
group in the early 1970s; however, the wrong structure of 1 was proposed (Fig. 
 
Fig. 2. Structure of artemisinin. 
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2).13 The structure of ART was elucidated in 1979 by X-ray analysis, which was 
supported by total synthesis.14 Since then, many total syntheses have been achi-
eved,15 including the newest one.16 ART is an erythrocytic schizonticide which 
exhibits rapid activity against all types of human and most animal malaria. It is 
effective against both CQ-sensitive (CQS) and CQR strains of P. falciparum 
((IC50) D6 = 9.0 nM, W2 = 6.7 nM, TM91C235 = 13.0 nM)17 and it has been 
successfully used for the treatment of severe cerebral malaria.5c ART has poor 
solubility in water and it is administrated as a water or oil suspension. Better re-
sults were achieved when it was administered intramuscularly (i.m.) as a suspen-
sion in oil, than orally (p.o.) in water. Metabolites isolated after p.o. adminis-
tration were devoid of peroxide function and had no antimalarial activity, strong-
ly suggesting that the peroxide function is a critical part of the pharmacophore. It 
was assumed that the good activity of 1 was due, at least partially, to its amphi-
philic structure that facilitates cell membrane permeability. The shortcoming of 
the usage of 1 is the high recrudescence rates related to its pharmacokinetic 
profile, which is characterized by a short half-life, low oral bioavailability and 
auto-induction of metabolism. 
3.1. First generation of artemisinin derivatives 
The first semi-synthetic derivatives of ART were simple ethers (3), esters (4) 
and carbonates (5) of dihydroartemisinin (DHA, 2) (Scheme 1).4b,5a DHA is a 
lactol easily obtained from 1 by NaBH4 reduction. It is twice as active as ART 
but exhibits a relatively high degree of neurotoxicity. In spite of poor oral bio-
 
Scheme 1. Transformations of artemisinin into first generation derivatives (SD90 – the dose 
required for 90% suppression of parasitemia; data taken from ref. 4b. Compounds were 
administred i.m. as oil suspension to mice infected with P. berghei). 
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availability, high recrudescence and noteworthy reports on its neurotoxicity, DHA 
is as effective against severe cerebral malaria as ART. 
Artemether 3a and arteether 3b are β-alkyl ethers of DHA designed to in-
crease lipid solubility, pharmacokinetic profile and antimalarial activity as com-
pared to 1 and 2. Both derivatives are fast acting blood schizonticides and are 
especially active against CQR strains. Some studies indicated significant neuro-
toxicity when the drugs were administered in high doses, probably due to their 
metabolism to DHA. Later studies showed that neurotoxicity occurred when the 
compounds were administered at least five times higher doses than is recom-
mended. Today, artemether 3a is the most widely used derivative and is applied 
as an oil solution for i.m. injection (Artenam® and Artemos®), or recently in 
combination with lumefantrine (Coartem®). 
Although carbonates 5 exhibited higher in vivo activity than 1, 2 and 3, there 
is no reported clinical application, probably because of their low stability under 
physiological conditions, due to their rapid hydrolysis to 2. 
For treatment of severe forms of malaria, water-soluble derivatives of ART, 
such as sodium artesunate 4c4b and artelinic acid 6,18 are indispensable. Both 
compounds can be administered intravenously (i.v.) and thus can be delivered 
much faster and be more efficacious than less polar ones which are administered 
i.m. as an oil suspension. 
Artesunate 4c (Fig. 3) rapidly diminishes parasitemia and is very efficacious 
in the restoration to consciousness of comatose cerebral malaria patients.19 Its 
shortcoming is high recrudescence of the disease and 4c is normally used in com-
bination therapies with mefloquine5e and amodiaquine (Arsucam®). Na artesu-
nate is used as a freshly prepared solution in dextrose or saline because of its 
rapid hydrolysis to 2. 
Artelinic acids 6a (Fig. 3) possess a C(10) β-ether linkage and are thus hyd-
rolytically more stable than artesunate 4c. The acid 6a expresses in vitro activity 
comparable to 1 and 4c against D6 and W2* strains of P. falciparum, but showed 
superior in vivo activities against P. berghei as compared to both compounds.18 
Moreover, the acid 6a has a longer plasma-life,18 a higher plasma concentration, 
higher binding capacities and the lower toxicity among the first generation of 
semi-synthetic derivatives of ART 1.5c Although the methyl ester 6c exhibits 
higher in vitro activity, it is less suitable because of its low solubility in water. 
The described derivatives suffer from serious disadvantages − short plasma 
life and CNS toxicity as consequence of their rapid metabolism into dihydroART 
2.20 Ethers 3 are metabolized by cytochrome P-450, forming the C(α)-hydroxyl 
derivative 7, which is later transformed into 2 (Scheme 2). Esters 4 simply hyd-
                                                                                                                    
* D6 (Sierra Leone strain) is resistant to mefloquine and susceptible to chloroquine, pyrime-
thamine and sulfadoxine; W2 (Indochina strain) is resistant to chloroquine, quinine, pyrime-
thamine and sulfadoxine and susceptible to mefloquine. 
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rolyze to 2. In addition, all these derivatives possessing acetal or hemi-acetal 
group in the D-ring readily hydrolyze under acidic conditions after p.o. adminis-
tration. The longer plasma half-life of artelinic acid 6a is probably the result of 
steric hindrance and poorer accessibility to P-450. The second generation of se-
mi-synthetic derivatives of ART was designed to overcome these disadvantages. 
 
Fig. 3. Structures and antimalarial activities of derivatives 4a and 6. 
 
Scheme 2. Metabolic transformations of derivatives 3, 4 and 7. 
3.2. Second generation of artemisinin derivatives 
The first efforts towards metabolically stable compounds included a modifi-
cation of artelinic acid 6.20 The new compounds (Fig. 4) exhibited higher activity 
against the W2 than against the D6 clone. It was found that electronic effects, the 
 
Fig. 4. Structures and antimalarial activities of derivatives 8–10 (ED50 – effective dose, 
the dose that decreases parasitemia by 50 %). 
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configuration at C(α) (the (S)-isomers were more active than the (R) ones), lipo-
philicity and steric factors have a considerable influence on the antimalarial acti-
vity. The most active compound 8 was 10, 20 and 40 times more active than 
compounds 3b, 1 and 6a, respectively. 
Replacing the O-alkyl group with an O-phenyl group should prevent oxida-
tive dealkylation with P-450 and the formation of dihydroartemisinin 2. Conse-
quently, a series of C(10)-aryloxy derivatives 9 and lactams 10 were synthesized 
and their antimalarial activity assessed (Fig. 4).21 Derivative 9 was in vitro as 
active as artemether but had outstanding in vivo antimalarial activity, which was 
higher than the clinically used sodium artesunate. Moreover, derivative 9 was 
metabolically more stable than the parent compound (H instead of CF3). 
Many 11-azaartemisinins 10 (Fig. 4) were described as being more stable 
under physiological conditions.22 In addition, the possibility of changing the 
substituents on the nitrogen enabled the fine-tuning of the activity. New com-
pounds 10a and 10b were, respectively, 26 and 22 times more active then 
ART.22b 
The superior activity of deoxoartemisinin 1123 encouraged the synthesis of a 
series of C(9)-substituted derivatives 12 (Fig. 5).24,25 Derivatives 12a–b were 
21–33 times more active than ART against the W2 clone and 50–70 times more 
active against the D6 clone, clearly demonstrating that the removal of the lactone 
carbonyl provides excellent potency enhancement.25 These and some new deri-
vatives25 were tested in vivo both s.c. and p.o. The activity of derivative 12a was 
superior to that of ART, curing all mice at an 8 mg/kg/day s.c. dose. 
 
Fig. 5. Structures and antimalarial activities of derivatives 11 and 12. 
A series of C(10) carbon heterocyclic substituted derivatives (Fig. 6) of de-
oxyartemisinin were synthesized using a short and efficacious synthetic proce-
dure.26 The compounds were tested in vitro against the CQ-sensitive (CQS) 
NF54 P.f. strain and demonstrated activity at least that of ART. Derivative 13a 
was the most active in the series with IC50 = 1.4 nM. A special group of these 
derivatives were of dimeric structure. The compounds were more stable under 
physiological conditions than the parent compound 1 and simultaneously retained 
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very good to excellent activity.27 Some of these derivatives were significantly 
more active (IC50 = 1.3–3.2 nM) than ART (IC50 = 9.9 nM) against the CQS 
NF54 P.f. strain. 
 
Fig. 6. Structures and antimalarial activities of derivatives 13. 
3.3. New artemisinin derivatives 
With the aim of preventing metabolic transformation of artemisins to dihyd-
roartemisinin 2 and thus avoiding neurotoxicity, several 10-(alkylamino)artemi-
sinins 14 were designed (Fig. 7).28,29 All the tested compounds showed excellent 
in vivo activities against P. berghei, with 14c, as the most active derivative, being 
almost 25 times (s.c.) and 7 times (p.o.) more active than artesunate 4c. Unfor-
tunately, 14c suffers from being seriously neurotoxic even at low doses, thus in-
dicating once again that the more lipophilic compounds are more toxic.29 How-
ever, derivative 14e (artemisone) showed no toxicity and possesses tractable phy-
sicochemical properties. In vivo experiments revealed that artemisone has a 
greatly enhanced bioavailability, as reflected in the greater and significantly more 
sustained activity in plasma as compared to other artemisins. Moreover, in 3-day 
combinations with mefloquine (5 mg/kg) or amodiaquine (20 mg/kg), a single 
oral dose of artemisone (10 mg/kg) completely cured infected monkeys.29 
A series of C(10)-ether derivatives 15 (Fig. 8) possessing voluminous lipo-
philic groups were tested p.o. against multi-drug resistant P. yoelii nigeriensis 
and several of them were 2 to 4 times more active than β-arteether.30 Most active 
were the 15a and 15b derivatives that afforded 100 % protection at a 12 mg/kg×4 
day dose. The least active derivative was the corresponding β-isomer of 15a.  
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Similar relative relationships between α- and β-epimers were observed with 
other derivatives described in this study, which is in sharp contrast to the activity 
profile of arteether, where the β-isomer showed higher activity than the α-isomer. 
The corresponding C(10)-esters 16 (Fig. 8) were more active in vivo than β-arte-
ether against P. yoelii nigeriensis, with 16c being the most active derivative with 
4/5 cured mice at 12 mg/kg×4 day p.o. dose.31 Comparing the members of the 
two series, the structurally similar esters were less active than the corresponding 
ethers (16a vs. 15a, and 16b vs. 15b). 
 
Fig. 8. Structures of derivatives 15 and 16. 
Hydrolytically stable C(10)-nonacetal artemisinin dimers 17 (Fig. 9), which 
possess phthalate derivatives as linker, showed higher in vitro antimalarial acti-
vities against the CQS NF54 P. falciparum strain than ART 1, with 17a and 17b 
being the most active.32 These two dimers were, respectively, 3 times and 37 ti-
mes more efficacious than artesunate 4c when administered s.c. and 17b was 1.5 
times more efficacious than 4c (p.o.). 
A new generation of ART dimers with excellent in vivo activity in P. ber-
ghei infected mice was developed.33,34 Eleven new derivatives 18–24 (Fig. 10) 
showed curative activity at a 3×30 mg/kg oral dose. At this dose, the average 
 
Fig. 7. Structures and antimalarial activities of derivatives 14. 
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mouse survival period was ≥ 3 times longer in comparison to artesunate 4c (> 30 
days for derivatives 18–24 vs. 7 days for 4c).34 
 
Fig. 9. Structures and antimalarial activities of dimers 17. 
 
Fig. 10. Structures of derivatives 18–24. 
4. 1,2,4-TRIOXANES 
Very important finding was the high antimalarial activity of trioxanes. These 
compounds have a much simpler structure than the ARTs, e.g., the trioxanes 25–
–29 (Fig. 11).35–38 The activity data significantly contributed to the understand-
ing of the minimum structural requirements for exhibition of good antimalarial 
activity. The results strongly indicate that ring D and the lactone ring are of no 
importance for good antimalarial activity, but all derivates confirmed the impor-
tance of the unique 1,2,4-trioxane structure. The results showed that small stereo 
or structural differences have a significant contribution to the activity, e.g., epi-
mers 25 showed different in vitro activity35 (particularly significant against the 
CQS strain D6), or in the case of derivatives 26, in which the methyl substituents 
are replaced with the spirocyclopentyl group (26a vs. 26b).35 Contrary to the ob-
served stereoselectivity, the enantiomers of 27a and 27c or 27b and 27d showed 
very similar activities, suggesting that cis-fusion significantly contributes to the 
activity.36 Probably the most interesting example is represented by epimers 28, 
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where the change of the configuration at one stereocentre dramatically changed 
the activity.37 A similar structure-activity relationship, SAR, could be developed 
for 29 and 30.38 
 
Fig. 11. Structures and antimalarial activities of derivatives 25–30. 
Structurally similar to the cis-fused trioxanes 27, the trans-fused derivatives 
31–34 (Fig. 12) also exhibited high activities.39 They caused a 96–100 % sup-
pression of parasitemia on day 4 after a 96 mg/kg/day p.o. dose, with the spiro-
cycloheptane 33 as the most active. Although trioxanes 31–34 are somewhat less 
effective than β-arteether under the same test conditions (100 % of suppression at 
 
Fig. 12. Structures and antimalarial activities of derivatives 31–43. 
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48 mg/kg/day), the obtained results suggested that trans-fusion may also provide 
good antimalarial activity and that some other structural aspects should addi-
tionally be taken into consideration. Accordingly, the cis-fused trioxane 35 (Fig. 
10) showed IC50 and IC90 values of 893 nM and 1845 nM, respectively, against 
the W2 P. falciparum clone, while under the same screening conditions, the cis- 
-fused trioxane 27a showed corresponding values of 15 nM and  36 nM, res-
pectively.40 
Trioxanes 36–43 (Fig. 12) were obtained due to efforts aimed at creating pe-
roxides with a simpler structure but still sufficiently active for treating malaria. 
Using different starting materials, such as geranyl acetate41 (trioxanes 36), cyc-
lopropyl or cyclohexyl allylic alcohols42 (trioxanes 37), aryl substituted allyl al-
cohols (trioxanes 38)43 or methyl substituted allyl alcohols (trioxanes 39 and 
40)44 for obtaining β-hydroxyhydroperoxides which were later coupled to differ-
rent carbonyl compounds, very active trioxanes with diverse structures were ob-
tained.45,46 Of all the given examples, the most active were the 2-adamantyl 
derivatives. Derivatives 36–38 were tested against multidrug resistant P. yoelli in 
mice and exhibited 100 % suppression of parasitemia on day 4 at 96 and 48 
mg/kg×4 days (Peter’s test) doses p.o. The most active 2-fluorenyl derivate 38c 
showed 100 % of suppression of parasitemia on day 4 even at 24 mg/kg×4 days, 
which appears to be the half effective dose of arteether.43 Intramuscular injection 
decreased the activity of these derivatives and thus confirmed, once again, that 
hydrophobic compounds show better bioavailability on oral administration. Deri-
vatives 39 and 40 with a C(5)-alkyl substituted 1,2,4-trioxane ring were tested 
against the CQR K1 P.f. strain and showed activities which strongly depended on 
the C(3)-substituent. While the spiroadamantane derivates 39 were as active as 
ART 1, the gem-dimethyl derivative 40 was 270 times less active.44 Replacing 
the spiroadamantyl with a spirocyclohexyl group bearing an ionisable arylamino 
moiety, as in 42,45 or other polar groups, as in 43,46 also resulted in loss of ac-
tivity. Although some derivatives, such as 43a and 43b46 that exhibit 100 % sup-
pression of parasitemia on day 4 at 96, 48 and 24 mg/kg×4 days doses p.o., were 
active, in general, these compounds were less potent than the adamantyl deriva-
tives. These results convincingly introduced the adamantyl-spiro-1,2,4-trioxane 
motif as a significant contributor to good antimalarial activity. 
The antimalarial activity of a series of steroids possessing the 1,2,4-trioxane 
moiety 44–46 (Fig. 13) was also tested.47 Only the pregnane-based trioxanes 
45a–f expressed good activity. They showed 100 % suppression of parasitemia 
on day 4 and 40–100 % protection at a 96 mg/kg×4 days dose, with 45b being 
the most efficacious. Cholestane- and tigonenin-based derivatives were much less 
successful with 15–73 % suppression. 
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Fig. 13. Structures of steroid-based 1,2,4-trioxanes 44–46. 
5. 1,2,4-TRIOXOLANES 
1,2,4-Trioxolanes, the ozonides, are a very well known class of organic com-
pounds. They are intermediates in the transformation of olefins into carbonyls 
during ozonolysis. It was an unexpected and surprising discovery48 that ozonides 
are stable enough and that some of them express excellent activity against the 
malaria parasite, as do the structurally similar 1,2,4-trioxanes. Moreover, these 
compounds were more active than artesunate 4c and artemether 3a, both in vivo 
and in vitro. The compounds 47–49 (Fig. 14) showed superior pharmacokinetic 
results, such as prolonged half-life and enhanced bioavailability after a single 
oral dose. The derivative 49 had inferior antimalarial results and a higher recru-
descence level compared to 48, however, it was chosen as the development can-
didate primarily because of its improved toxicological profile and reduced con-
centrations in brain tissue after oral dosing.48 The other derivatives 50–53 (Fig. 
14) afforded further insight into SAR in the context of the physicochemical, 
biopharmaceutical, and toxicological profile of trioxolanes.49 Interestingly, it was 
 
Fig. 14. Structures and antimalarial activities of derivatives 47–55. 
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shown that symmetrically substituted derivatives 54 and 55 (Fig. 14) were sig-
nificantly less active than their non-symmetrical counterparts,49 thus confirming 
an earlier observation of higher activity of non-symmetrical substituted pero-
xides.50 
The tolerance of the 1,2,4-trioxolane moiety to diverse synthetic condi-
tions51 enabled the synthesis of a significant number of derivatives and some of 
them showed very good in vitro and in vivo activities, e.g., the derivatives 56– 
–60,52 the piperidine derivatives 61–6353 and derivatives containing aliphatic 
and aromatic amino functional groups or azole heterocycles as substituents (64– 
–70) (Fig. 15).54 The lack of activity of 71 indicates the essential contribution of 
the spiro-adamantane system to the antimalarial properties of this class of com-
pounds.54 As the authors concluded from the obtained results, in vitro activities 
are not always a reliable predictor of in vivo potency.52, 54 Many of the examined 
derivatives showed excellent in vitro results but failed during in vivo tests, toxi-
 
Fig. 15. Structures and antimalarial activities of derivatives 56–71. 
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city trials or metabolic stability and bioavailability tests. The more lipophilic tri-
oxolanes tend to have better oral activities but are metabolically less stable than 
their more polar counterparts are. Such behaviour is consistent with results ob-
tained for other classes of synthetic peroxides. Trioxolanes with a wide range of 
neutral and basic groups had good antimalarial profiles, contrary to derivatives 
with acidic groups. 
6. 1,2,4,5-TETRAOXANES 
3,6-Substituted derivatives of 1,2,4,5-tetraoxacyclohexane (1,2,4,5-tetraoxa-
ne) have been known for many years and were used for different purposes.55 
They are readily formed by acid-catalyzed peroxyacetalization of carbonyl com-
pounds with hydrogen peroxide or bis-trimethylsilylperoxide.56–58 The discovery 
that inexpensive 3,6-dicyclohexylidene tetraoxanes exhibited pronounced anti-
malarial activity opened new possibilities in combating this pestilence.59 Since 
then, many efforts have been made to find better procedures for synthesizing and 
designing new derivatives with improved activities.60,61 Many of them were re-
viewed and their antimalarial activities analyzed.5f,5g,62 
After the first report in which they were described,50,63 mixed tetraoxanes* 
have acquired significant attention.62 Since then, some new procedures for their 
synthesis,64,65 or the synthesis of gem-dihydroperoxides as key precursors66 have 
been developed with aim of improving the yields of tetraoxane compounds. 
A new group of mixed dicyclohexylidene tetraoxanes, bearing polar neutral 
or basic groups, demonstrated high activities against both CQS and CQR P.f. 
strains (Fig. 16).67 The compounds were designed with the aim of obtaining the 
simplest amphiphilic structures of the kind and to minimize the influence of ste-
ric effects on the antimalarial activity. In addition to this, a thorough examination 
                                                                                                                    
* The term “mixed tetraoxanes”describes 1,2,4,5-tetraoxacyclohexanes differently substituted 
at positions 3 and 6.50 
 
Fig. 16. Structures and antimalarial activities of derivatives 72–81. 
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of the chemical stability under basic and acidic conditions, and under oxidative, 
reductive and reductive amination conditions revealed a significant stability of 
the tetraoxane moiety that enabled the synthesis of variety of derivatives.67c 
Interestingly, the most active compounds within the group of dicyclohexylidene 
tetraoxanes 72–81 have very similar activities irrespective of the presence of neu-
tral (74, 79), polar protic (73) or a basic ionisable group (72, 75–78, 81). Such 
behaviour impedes profound SAR analysis. In the present set of derivatives, 
amines 75 and 76 were the most active in vivo. They both cured 5/5 mice at 300 
mg kg–1 day–1 doses s.c.* with 150 mg kg–1 day–1 doses s.c., 75 retained the 
same efficiency but 76 was less active with 4/5 cured mice. 
A structurally similar group of cyclohexylidene mixed tetraoxanes was syn-
thesized68 using a procedure previously applied to this class of compounds (Fig. 
17).50,67a The compounds were screened against CQS P.f. strain 3D7 and the 
most active derivatives 82–88 had activities within the same range as the ones 
described above. Monospiro tetraoxanes that exhibited a much lower antimalarial 
potency (87 and 88) confirmed the superiority of the 3,6-dispiro-1,2,4,5-tetra-
oxane structural motif. Adamantyl derivatives 85 and 86 showed 100 % inhibi-
tion on p.o. administration at 30 mg kg–1 doses and derivative 86 had better ED 
values against P. berghei (ANKA) as compared to artemether: ED50 = 3.18 mg 
kg–1 and ED90 = 3.88 mg kg–1 for 86; ED50 = 5.88 mg kg–1 and ED90 = 10.57 
mg kg–1 for artemether. 
 
Fig. 17. Structures and antimalarial activities of derivatives 82–88. 
The ability of adamantyl substituent to stabilize the structure and to improve 
the antimalarial activity was additionally exemplified with a new series of am-
phiphilic adamantyl-based mixed tetraoxanes (Fig 18).69 The derivatives that 
contain polar sulphonamide groups at one end and a highly lipophilic adamantyl 
                                                                                                                    
* Modifed Thompson test. “Cure” is defined as a mouse alive at day 31 with no parasitemia. 
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group at the other end exhibit activity in the 3–30 nM range, with 89–92 as the 
most active compounds against the 3D7 P. f. strain. In addition, derivative 89 
was tested versus seven additional strains of P. falciparum and exhibited activity 
in the 1.9–3.8 nM range. Compounds 89 and 91 were noticeably active in vivo 
(p.o., P. berghei ANKA): ED50 = 6.61 mg kg–1 for 89 and ED50 = 7.93 mg kg–1 
for 91, ED50 = 8.42 mg kg–1 for ART. 
 
Fig. 18. Structures and antimalarial activities of derivatives 89–92. 
Some other types of tetraoxanes were less successful as antimalarials. Such 
examples are symmetrically substituted 3,3,6,6-tetraalkyl-1,2,4,5-tetraoxanes de-
rived from acyclic ketones70 and symmetric and non-symmetric 1,2,4,5-tetraoxa-
ne derivatives of substituted benzaldehydes (Fig. 19).71 The compounds were tes-
ted as mixtures of the corresponding isomers and, in general, exhibited rather 
poor antimalarial activity against both CQS and CQR P. falciparum strains. Within 
the series of acyclic derivatives, compounds 93–95 were the most active but still 
they were 1.6–2.2 times less active than the corresponding tetraoxanes 96 derived 
from cyclohexane, and 40–50 times less active than artemether.70 Within the 
benzaldehyde series, compound 97 was the most active, while the other members 
were significantly less active with IC50 values in the range 1.4–17 μM,71 which 
is far less than the corresponding 1,2,4,5-tetraoxanes or 1,2,4-trioxanes consi-
dered as active. Nevertheless, these results offer valuable basic information for 
the correlation between structure and antimalarial activity of the simple peroxides. 
 
Fig. 19. Structures and antimalarial activities of derivatives 93–97. 
2009 Copyright (CC) SCS
___________________________________________________________________________________________________________________________
Available online at www.shd.org.rs/JSCS/
 ANTIMALARIAL PEROXIDES 1173 
1,2,4,5,7,8-Hexaoxonanes are customary side products of the synthesis of 
1,2,4,5-tetraoxacyclohexanes (Fig. 20). Their activities against K1 and NF54 P. f. 
strains showed that hexaoxonanes 98–103 are convincingly less active than the 
corresponding tetraoxanes, with 3–4 orders of magnitude lower IC50 values.72 
Since peroxide bonds are essential for antimalarial activity, such poor efficiency 
was attributed to steric hindrance of the peroxide bonds. An analogous behaviour 
was also noticed with the asymmetric 1,2,4,5,7,8-hexaoxonane 104.67c 
 
Fig. 20. Structures and antimalarial activities of derivatives 98–105. 
The first described steroidal 1,2,4,5-tetraoxanes 106 and 107 were deriva-
tives from 5α-cholestane-3-one (Fig. 21).58 Although tetraoxane 106 was less ac-
tive in comparison to ART (IC50 (D6) = 155 nM), the results of this pioneering 
research clearly showed that even complex molecules such as steroids could be 
good carriers of the tetraoxane pharmacophore. Replacing cholestane with deri-
vatives of cholic acid significantly improved the antimalarial activity (Fig. 21).57,73 
The compounds obtained as series of diastereomers, named as cis-C(2)C(2a) and 
trans-C(2)C(2a), showed moderate to high activity against both CQS and CQR 
strains. The most active were the primary amide 108 (IC50 (W2) = 18.79 nM) 
and the n-propyl amides 109 and 110 (IC50 (D6) = 9.29 nM and 20.08 nM, res-
pectively). 
 
Fig. 21. Structures of derivatives 106–110. 
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Replacing one steroid with a simpler alkylidene moiety enabled the synthesis 
of the second generation of steroidal tetraoxanes based on cholic acid derivatives. 
Starting from 4-alkyl,50,74 4-aryl,75 4-carboxy substituted cyclohexanones76 and 
the acetone77 afforded the synthesis of a numbers of various derivatives (Fig. 22). 
The stability of the tetraoxane moiety under a range of reaction conditions en-
abled the synthesis of diverse derivatives.67c Some of the shown mixed steroidal 
tetraoxanes exhibited impressive in vitro and in vivo antimalarial activity. The 
contribution of the cholic acid moiety as carrier is clearly emphasized by the pro-
nounced activity of derivative 118; bis-isopropylidene tetraoxane was completely 
inactive.78 
 
Fig. 22. Structures and antimalarial activities of derivatives 111–123. 
When administered to mice (p.o., P. berghei KBG 173 strain), tetraoxane 
112 cured 4/5 mice at 200 mg kg–1 day–1 doses,* while being moderately active 
                                                                                                                    
* Modifed Thompson test. “Cure” is defined as a mouse alive at day 31 with no parasitemia. 
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when applied at 50 mg kg–1 day–1 (cured 2/5).50 The administration of tetra-
oxane 117 (p.o.) produced 2/5 cured mice at 320 mg kg–1 day–1 doses, however, 
the same compound was more efficient at 160 mg kg–1 day–1 s.c. doses with 5/5 
cured mice.77 All the cured mice had negative blood smears during all the test 
days (6–31). Tetraoxane 120 cured 5/5 mice at 320 mg kg–1 day–1 and demons-
trated moderate activity using lower doses (80 mg kg–1 day–1) with 3/5 cured 
mice.74 It should be emphasized that all these compounds showed no toxic ef-
fects towards the tested animals at any applied concentration. In addition, they 
have low activity against the Vero cell line, exhibiting a cytotoxicity/antimalarial 
potency ratio 1/(1400 – 9500).50 Furthermore, the n-propyl amide 113 revealed 
no healthy erythrocyte (RBC) membrane lysis,79 suggesting that the antimalarial 
activity of these compounds was the consequence of interaction specific to infec-
ted RBC, and was not the result of uncontrolled RBC membrane lysis. 
A series of tetraoxanes based on deoxycholic derivatives were prepared with 
the aim of comparing them to cholic acid-derived tetraoxanes (Fig. 22).74 In 
general, these compounds follow the same trends as the cholic acid derivatives: 
higher activity of the 4”-methylcyclohexyl derivatives than the non-substituted 
cyclohexyl ones and higher activity of 4”R- over 4”S-epimers. However, tetra-
oxanes with deoxycholic acid-derived carriers are less active than the corres-
ponding cholic acid derivatives suggesting that the C(7) acetyloxy group appre-
ciably contributes to their antimalarial activity. Within this group of tetraoxanes, 
the derivatives 121 and 122 were the most active exhibiting activities similar to 
ART and mefloquine. In vivo, compound 122 cured 3/5 mice at 160 mg kg–1 
day–1 doses (p.o., P. berghei KBG 173 strain), however, at lower doses of 40 mg 
kg–1 day–1, the activity declined sharply with no cured mice. 
The only intramolecular steroidal 1,2,4,5-tetraoxane 123 (Fig. 22) hitherto 
tested* exhibited moderate in vitro antimalarial activity against P. falciparum 
strains (IC50 (D6) = 0.63 μM; IC50 (W2) = 0.52 μM).80a 
7. CHIMERIC PEROXIDE–QUINOLINE COMPOUNDS 
A new concept for treating malaria was introduced with the chimeric pe-
roxides, compounds that possess covalently bonded two well-known pharmaco-
phores – the quinoline functionality and an appropriate peroxide moiety. The 
compounds were designed with the aim of overcoming resistance of the parasite 
to CQ-based drugs and to take advantage of the pharmacokinetic properties of 
trioxanes, ozonides and tetraoxanes. The initial set of derivatives were more ac-
tive than chloroquine against CQR strains, with compound 124 being the most 
active on both laboratory strains81 and on human isolates (Fig 23).82 
                                                                                                                    
* After submission of the manuscript, the authors became aware of new intramolecular tetra-
oxanes prepared by the Russian group: Alexander O. Terent’ev, Dmitry A. Borisov, Vladimir 
V. Chernyshev, Gennady I. Nikishin, J. Org. Chem. 74 (2009), doi jo900226b. 
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Fig. 23. Structures and antimalarial activities of derivatives 124–132. 
Certain simplifications of structure lead to trioxaquine 126 that was very ac-
tive against both CQS and CQR strains of P. falciparum:83 ED50 = 5 and 18 mg 
kg–1 day–1 (P. vinckei), i.p. and p.o. administration, respectively. Parasitemia 
clearance, without recrudescence, was achieved after an 18 mg kg–1 day–1 i.p. 
dose and no toxic effect in mice was observed even at 120 mg kg–1 day–1 p.o. 
dose over four consecutive days. Coupling of the same trioxane ketone and pri-
maquine produced trioxaquine 127, which demonstrated significantly lower ac-
tivity against all three examined strains, and thus limited this concept to only 
4-aminoquinolines. Trioxaquine 128 also exhibited high in vitro and in vivo ac-
tivity.84 The compound completely cured mice infected with CQR strain P. 
vinckei and CQS strain P. vinckei at 30 mg kg–1 day–1 p.o. doses. 
Other variations in the trioxane structure produced derivatives 12985 and 
130,86 which expressed lower activities than the previously described derivatives. 
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Although some very active trioxaquines were prepared, the concept of these 
drugs did not justify itself for several of reasons. First, these compounds did not 
show the expected synergism since in many cases the parent trioxane keto-
nes78,86 were more active than the hybrids, see ketone 125 vs. chimera 124 for 
comparison. In addition, 4-aminoquinolines 131 are themselves antimalarials. They 
suppressed parasitemia in mice (i.m., 87–97 %) but, as with trioxaquines 130, no 
treated mice survived.86 Even though some authors wish to establish these chi-
meras as therapeutics with dual activity,84,87 all the available evidence on the 
mechanism of antimalarial activity of trioxanes and 4-aminoquinolines indicate 
that they have the same target.84 Lastly, many of these hybrid molecules were 
tested as inseparable mixture of diastereomers. These circumstances deprived one 
of the possibilities to realize the actual scope of the antimalarial capacity of these 
compounds. 
Based on the concept that the compounds have two integrated pharmaco-
phores and enhanced activities of trioxolanes with the basic side chain, chimeric 
trioxolane 132 was obtained (Fig. 23).88 Although it is very active in vitro 
against the K1 and NF54 strains and in vivo against the ANKA strain of P. ber-
ghei, 132 did not achieve a synergic effect of the two pharmacophores, especially 
when compared to trioxolanes 64 and 68. 
Another variation of trioxane hybrid antimalarials was made with covalently 
bonded dihydroartemisinin 2 and C(18)-quinine acid 133 (Fig 24).89 The two 
segments were bonded with a hydrolytically labile ester bond and it is possible that 
under physiological conditions, hybrid 134 actually delivers two active agents. 
This approach seems to be logical since there is evidence that ARTs and quinine 
are active in the same stage of the P. falciparum life cycle,90 but differ in the 
mechanism of their action.89 The obtained results showed that hybrid 134 had a 
significantly higher antimalarial activity than ART and quinine alone, or when it 
is compared to an equimolar mixture of ART and quinine. However, the ob-
 
Fig. 24. Structure and antimalarial activity of derivative 134. 
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served results would be more significant if the authors had compared hybrid 134 
to dihydroART 2 rather than ART and/or to acid 133. 
Based on data obtained from research into the mechanism of tetraoxane ac-
tion76 (vide infra), chimeric tetraoxaquines were designed with the aim of exa-
mining the effects of the presence of two pharmacophores within the same mole-
cule (Fig. 25).91 Three of them were as active as ART or mefloquine against the 
tested strains of P. falciparum and all of them showed higher activity than chlo-
roquine against CQR strains. Although a synergic effect was not achieved, it 
could be noted that derivatives exhibited higher activity than the corresponding 
non-chimeric derivatives (compare 135 to 72, 136 to 77 and 78, 137 and 138 to 
120).67c In vivo experiments (p.o., P. berghei KBG 173 strain) revealed that 
derivatives 135 and 136 cured all tested mice at 320 mg kg–1 day–1 doses. At the 
lower dose of 80 mg kg–1 day–1, the derivatives were less effective, however, but 
still cured 3/5 of the examined mice. Both compounds have a minimum active 
dose (MAD) of 20 mg kg–1 day–1 with no toxic effects even at the highest ap-
plied dose of 960 mg kg–1 day–1. 
 
Fig. 25. Structures and antimalarial activities of derivatives 135–138. 
8. METABOLISM AND DRUG COMBINATION ASSAYS 
Although a significant numbers of 1,2,4,5-tetraoxane antimalarials have been 
reported and some of them exhibited extraordinary antimalarial activity, their 
pharmacological properties have been much less explored than those of the 1,2,4-
-trioxanes. Vennerstrom was the first to give a detailed metabolic and pharmaco-
logical profile of the tetraoxanes.92 It was shown that compound 139 (Fig. 26) is 
synergistic with mefloquine and quinine against both CQS D6 and CQR W2 P. f. 
strains. Tetraoxane 139 is also synergistic with chloroquine, unlike ART that 
shows an additive interaction with chloroquine and synergism only at high con-
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centrations.93 In addition, 139 is synergistic with ART in contrast to other semi-
synthetic derivatives which have a uniformly additive effect. Derivative 139 is a 
modest inhibitor of human CYP1A2 activity and has a different metabolic path-
way to ART. Artemisinin induces its own metabolism92 and is metabolized by 
CYP2B6, CYP2C19 and, to the less extent, by CYP3A4. Tetraoxane 139 is most 
likely metabolized by CYP1A2 and, unlike artemisinin, 139, has prophylactic 
activity, protecting 4/7 mice against P. berghei. These results suggest that tetra-
oxanes have different metabolic pathways with regard to ART and may have a 
somewhat different mechanism of action. Šolaja et al. reported the results of a 
metabolic stability assay and metabolic identification for many cyclohexylidene 
and steroidal mixed tetraoxanes.67b,67c,74,76,77,91 Incubation of human, mouse, 
rat and rhesus monkey liver microsomes with the examined compounds showed 
dissimilar half-lives and various mono- and dihydroxylated products, as well as 
the products of dehydration and deacetylation, were also detected. Unfortunately, 
the results of the metabolic stability assays and proposed metabolite structures 
could not be correlated with the in vitro and in vivo antimalarial activities of 
these derivatives. It is important to note that no products of peroxide bond clea-
vage were detected. Drug combination assays of tetraoxane 140 (Fig. 26) showed 
that this derivative is additive with ART 1, dihydroART 2 and artesunate 4a 
against both CQS (D6) and CQR (W2 and TM91C235) P. falciparum strains; 
however, tetraoxane 140 showed synergism with artelinic acid 6a against all 
three strains.94 Tetraoxane 140 is additive with mefloquine under high concen-
trations against D6 and TM91C235, but at low concentrations it exhibits an anta-
gonistic effect. With chloroquine, tetraoxane 140 showed antagonism against all 
three tested strains. 
 
Fig. 26. Structures and antimalarial activities of derivatives 139–142. 
After incubation of ozonide 49 with human liver microsomes in vitro, three 
mono-hydroxylated metabolites were detected.95 Two major metabolites 141 and 
142 (Fig. 26) appeared after hydroxylation of the adamantane substructure. Both 
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141 and 142 had low antimalarial activity with IC50 values > 245 nM against the 
CQR K1 P. falciparum strain. 
Incubation of isotopically labelled artemisone 14e* with human liver micro-
somes after 30 min gave mono- and di-hydroxylated metabolites 143–147, with 
syn hydroxyl and peroxide groups (Scheme 3).29 Incubation with microsomes 
and 14 recombinant CYP isoforms together with selective inhibitors showed that 
only the recombinant CYP3A4 significantly metabolized artemisone, indicating 
that artemisone 14e and ART, in spite of being structurally similar, have different 
metabolic profiles in P. falciparum. The isolated metabolites were tested against 
the P. falciparum K1 strain and the results showed that metabolites 144 and 145 
exhibited similar activities to 14e (144: IC50 = 5.51 nM and 145: IC50 = 4.26 
nM; 14e: IC50 = 1.99 nM), but 143 was less active with IC50 = 61.55 nM. 
 
Scheme 3. Metabolic transformations of artemisone. 
It can be seen that a common denominator is an iron species in the haem 
prosthetic group, and during interaction of all these structurally diverse com-
pounds with CYP enzymes, scission of the peroxide bond never occurred. 
9. MECHANISM OF ACTION 
Many research groups were involved in solving the mechanism of action of 
antimalarial peroxides and many reports can be found on this subject. However, 
it was realized that the scientific literature is very controversial with many 
authors disagreeing about the site of action, the putative target and lethal reaction 
species, the actual killers of the parasite. 
Several groups investigated the mechanism of action for more than fifteen 
years. 36,37,96–100 In general, it was found that the process commences with the 
formation of oxygen radicals 148 and 149, which arise upon homolytic peroxide 
bond scission in the presence of ferrous ions (Scheme 4). It is assumed that ions  
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148 and 149 undergo intramolecular rearrangements (1,5-hydrogen shift and 
β-scission) to form C-radicals 150 and 151. Both the O- and C-centred radicals 
 
Scheme 4. Proposed mechanism of Fe(II)-induced decomposition of artemisinin and 
generation of lethal O- and C-radical species. 
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are highly reactive species and are lethal to the parasite. During these processes, 
one or more intermediates probably react with vital biomolecules, inhibit their 
activity and cause the death of the parasite. It was proved that one of the side 
products is a high-valent iron-oxo species Fe(IV)=O, which could also be toxic to 
the parasite.101,102 In the absence of a suitable target that would be alkylated, the 
products 152 and 153 were formed.100b The adducts 154–158 (Fig. 27) were 
found indicative for primary and secondary radicals and the ability of ART and 
its derivatives to act as alkylating agents.96c,99,100 The results obtained with ar-
tesunic acid and trioxaquine 126 additionally confirmed the capability of peroxi-
des or chimeras to alkylate haem.103 
 
Fig. 27. Structures of covalent adducts 154–158 derived from C-centred radicals. 
After incubation of erythrocytes infected with D6 or FCR3 P.f. strains and 
with isotope-labelled [10-3H]-2 or [15-3H]-3b, radioactivity was detected in pro-
tein fractions originating from the parasite.104 After treatment with EtSH or 8 M 
urea, it was concluded that the proteins and isotopic-labelled fragments of 2 and 
3b were covalently bonded. No radioactivity was detected after incubation with 
non-infected erythrocytes or with radiolabelled deoxoART. Some of alkylated pro-
teins were P. falciparum membrane proteins MSA-1, MSA-2, CRA.5.1, TCTP 
(translationally controlled tumour protein) and histidine-enriched protein (42 
kDa).105,106 TCTP possesses bonded haem and to some extent is present in FV 
membrane. Compound 2 reacted in vitro with recombined TCTP in the presence 
of in situ generated haem and formed a covalent adduct in a 1:1 ratio. The 
amount of covalent adduct decreased to 60 % when one of the cysteines was che-
mically blocked. 
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Results of very important research107 revealed that ART is a very effective 
inhibitor of sarco/endoplasmic reticulum calcium-dependent ATPase (SERCA) 
orthologue (P. falciparum ATP6) and that a catalytic amount of Fe(II) enhanced 
the inhibiting activity of 1. It was evidenced that a possible site of action of ART 
could be outside the FV and that the trigger for ART toxicity towards the parasite 
could be Fe(II) situated in the cytosol and not necessarily the free haem within 
the FV. 
In vitro resistance of 530 P. falciparum isolates from three countries (Cam-
bodia, French Guiana and Senegal) towards ART and its closest derivatives was 
investigated.108 It was found that the resistance was positively correlated only 
with a mutation of the SERCA P. falciparum ATPase6 genes and that P. falci-
parum ATPase6 is the target of ART antimalarials. All resistant isolates came 
from areas with uncontrolled use of ART derivatives. 
Artemisinin 1 and arteether 3b effectively inhibit FV proteolytic activity of 
enzymes that degrade haemoglobin, specifically cysteine-protease.109 Compound 
E-64 (for structure see ref. 110) a specific inhibitor of cysteine-protease is both a 
1 and 3b antagonist. These observations were further confirmed by ex vivo ex-
periments showing accumulation of haemoglobin in the parasites treated with 
ART, suggesting the inhibition of haemoglobin degradation. According to the 
above findings, it is not clear how artemisins and other peroxides would exert 
their antimalarial activity after reaction with free haem in the FV, when they 
inhibit the catabolism of haemoglobin and the liberation of haem. 
Recently,111 it was found that artemisinin, sodium artesunate and dihydro-
artemisinin react with haemoglobin (ferrous haem), but not with methaemoglobin 
(ferric haem) under standard solution conditions (50 mM phosphate buffer, pH 7, 
37 °C). The authors claim that the reaction selectively occurs at the haem sites 
and consists of the progressive, slow decay of the Soret band, as a consequence 
of haem alkylation and subsequent loss of π-electron delocalization. This finding 
further complicates the elucidation of the mechanism of action of artemisinins. 
Antimalarial activity does not necessarily correlate with chemical reactivity. 
Amino artemisinins 14a and 14b reacted readily with haem giving the expected 
products but derivatives 159 and 160 did not (Fig. 28).28,112 On the contrary, 
derivative 159 reacted with aqueous Fe(II) but 160, 14a and 14b were inert.28,113 
Very interesting information came from the discovery that compounds, such as 
161–164, which can generate neither primary nor secondary C-radicals, exhibited 
pronounced antimalarial activity.98 Similarly to the 10-deoxy derivative 159, ar-
temisone 14e readily reacted with aqueous Fe(II) affording the corresponding 
products.113 Both compounds reacted with Fe(OAc)2 and in the presence of the 
radical scavenger 4-oxo-TEMPO gave the corresponding covalent adducts (3 % 
for 159, 10 % for 14e and 73 % for 165). DFO, an iron chelator, antagonized the 
antimalarial activity of aqueous Fe(II)-susceptible artesunate and trioxane 159 
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but had no observable effect on either the aqueous Fe(II)-resistant derivative 160 
or on artemisone 14e.113 It was found that 14e efficiently alkylates haem.114 
 
Fig. 28. Structures and antimalarial activities of derivatives 159 – 165 
and selected derivatives 14. 
Due to the great specificity of ARTs to malaria parasite SERCA ATPase and 
inhibition of SERCA orthologues of P. falciparum (PfATP6) and P. vivax 
(PvSERCA), it was found that artemisone 14e is an even better inhibitor having 
Ki 1.7±0.6 nM for PfATP6 and Ki 0.072±0.012 nM for PvSERCA, in comparison 
to ART, Ki 169±31 nM for PfATP6 and Ki 7.7±4.9 nM for PvSERCA.29 In con-
trast to these derivatives, compound 160 has a low inhibitory activity for PfATP6 
(Ki 277±39 nM), which is in contrast to its high in vitro potency (IC50 3D7 = 
= 1.44).113 
Studies with conjugates 166–168 of ART derivatives, ozonides and 1,2,4,5- 
-tetraoxanes with acridine and nitrobenzyldiazole (NBD) fluorochromes (Fig. 29) 
showed that they accumulate only in infected erythrocytes, both within the cyto-
plasm and FV of the parasite.69,115 The formation of stabile adducts of acridine 
and NBD-tagged peroxides with biomolecules within the parasite was inhibited 
by co-incubation with the iron chelator DFO. In addition, the investigated pe-
roxides and their conjugates showed marked antagonism in combination with the 
iron chelators DFO and DFP.115 All the investigated conjugates showed high in 
vitro antimalarial activity in the 5–13 nM range against the 3D7 P. falciparum 
strain. These results suggest that both the cytoplasm and FV of the parasite could 
be equally the possible site of action of antimalarial peroxides, and that both 
haem from the FV or chelatable “free” iron from the cytoplasm could trigger the 
scission of the peroxide bond. 
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Fig. 29. Structures of conjugates 166–168. 
Adamantyl tetraoxane 169, ozonide 170 and 1,2,4-trioxane 171 (Fig. 30) were 
subjected to reaction with different ferrous salts. It was shown that the tetraoxane 
169 showed significant stability under the applied reaction conditions,69 while 
the ozonide 170 and the trioxane 171 readily reacted and formed secondary 
carbon radicals that were scavenged by TEMPO.116 
 
Fig. 30. Structures of peroxides 169–171. 
Ozonide 49 inhibits PfATP6 with a lower potency in comparison to ART, 
i.e., Ki (49) = 7.7 mM vs. Ki (ART) = 79 nM, which thus suggests that these two 
peroxides may have different mechanisms of action.117 However, the two com-
pounds have certain similarities, such as abrogation of the activity of 49 in the 
presence of DFO, antagonism in combination with DFO117 and the formation of 
a C-centred radical during reaction with Fe(II) and the formation of the corres-
ponding adduct with TEMPO.48 A fluorescent derivate of 49 was localized in the 
parasite cytosol in one parasite and in the FV in the other. In the cytosol, it was 
associated with the parasite endoplasmatic reticulum. In addition, the ozonide 49 
showed antagonism in combination with artesunate. 
A three-dimensional QSAR pharmacophore model for the antimalarial ac-
tivity of bis-steroidal and mixed steroidal 1,2,4,5-tetraoxanes was developed.118 
The model contains two hydrogen bond acceptors (lipid) and one hydrophobic 
(aliphatic) feature and maps well onto the potent analogues and many other ac-
tive peroxide antimalarials, such as ART, arteether, artesunic acid, and simpler 
tetraoxanes. It appears that the presence of at least one hydrogen bond acceptor in 
the trioxane or the tetraoxane moiety is a necessity for good activity of this class 
of compounds. Docking calculations with haem suggest that the proximity of the 
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Fe(II) and oxygen atom of the trioxane or the tetraoxane moiety favours potent 
activity of the compounds and that electron transfer from the peroxide oxygen is 
crucial for the mechanism of action. 
Differences between 1,2,4,5-tetraoxanes and the other peroxides were em-
phasised in studies of the mechanism of action of bis- and mixed steroidal tet-
raoxanes.76 Performing experiments under the same conditions as for other an-
timalarial active peroxides, unexpectedly the steroidal tetraoxanes generated only 
oxygen centred radical that did not further rearrange to a carbon centred radical. 
Using DMPO and DEPMPO, both O- and C-radical traps, EPR experiments re-
vealed only DMPO–•OR and DEPMPO–•OR spin-trapped adducts. As the only 
organic products, the corresponding starting ketones were isolated from the reac-
tion mixture and no traces of rearranged products that would result from C-ra-
dical intermediates were detected. Indirect evidence of the existence of high va-
lent Fe(IV)=O species was obtained from the rearrangement HMDB → HMB. 
Based on these evidences, two pathways (Scheme 5) were proposed, in which it 
was suggested that tetraoxane peroxides serve as an RO• radical source, as well 
as the source of the Fe(IV)=O species. RO• radical species are capable of mem-
brane hydroperoxidation (RBC membrane, parasite membrane, cytosol, or FV) or 
possibly attack other vital biomolecules. 
 
Scheme 5. Proposed mechanism of action of tetraoxanes. 
10. CONCLUSIONS 
Synthetic and semi-synthetic peroxides are effective drugs and are employed 
with success in the treatment of severe malaria. They are especially efficient 
against CQR strains of P. falciparum, the cause of cerebral malaria. Accessi-
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bility, relatively inexpensive preparation and the stability of 1,2,4-trioxane and 
1,2,4,5-tetraoxane function to a broad spectrum of reaction conditions enables the 
syntheses of derivatives with diverse structures and makes possible the discovery 
of even more effective drug(s). All authors emphasized the low toxicity of these 
compounds with rare cases of unwanted side effects. To date, there are no major 
examples of the appearance of resistance of Plasmodium species, except in the 
cases when drugs were used without proper control. These facts, together with 
the possibility for combination with other non-peroxide drugs, chiefly aminoqui-
nolines, open unrestricted possibilities in combating malaria. 
Reported results concerning the mechanism of antimalarial peroxide action 
are contradictory at a first glance. However, bearing in mind that the compounds 
differ significantly in their structures that are responsible for different log P va-
lues, bioavailability, passage through cellular membranes and stereospecific in-
teractions with assumed receptors or trigger species, the observed differences are 
logical. In our opinion, antimalarial peroxides may themselves have different ac-
tion pathway and they may have different targets. This said, certain common be-
haviour, such as the capability of acting as alkylating agents, is not excluded. In 
addition, this does not exclude the possibility that one compound is simultane-
ously activated against several different targets. Perhaps it should not be expected 
that all peroxides could be fitted into a unique mechanism of action. It is more 
likely that they have a complex, multi-targeted mechanism, including oxidative 
stress.113 
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И З В О Д  
ПЕРОКСИДНИ АНТИМАЛАРИЦИ 
ДЕЈАН М. ОПСЕНИЦА1 и БОГДАН А. ШОЛАЈА2 
1
Institut za hemiju, tehnologiju i metalurgiju, Univerzitet u Beogradu, Wego{eva 12, Beograd i 
2
Hemijski fakultet, Univerzitet u Beogradu, Studentski trg 16, p. pr. 51, 11158 Beograd 
Ширење маларије је стално присутан проблем на глобалном нивоу. Од маларије го-
дишње оболи 40 % светске популације и око 1,5–2,7 милиона људи умре. Према подацима 
Светске здравствене организације, 90 % смртних случајева је у земљама подcахарске Афри-
ке, међу којима доминирају деца старости до 5 година. Услед немогућности развоја вакцине, 
хемотерапија остаје као једини поуздан облик лечења од ове болести. Последњих година 
проблем борбе против маларије постаје ургентан из бројних разлога, међу којима је најзна-
чајнији развој хлорокин-резистентних сојева паразита. Откриће да артемизинин (АРТ, 1) и 
његови деривати показују изузетну ефикасност према хлорокин-резистентним сојевима 
отворило је велике могућности у борби против маларије. Од тада, посебно током 80-тих го-
дина, синтетисан је велики број једињења и резултати њихове aктивности описани су у мно-
гим научним публикацијама. Осим тога, у клиничкој пракси нису забележени примери по-
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јаве резистенције паразита према овој класи антималарика. У овом ревијалном раду описани 
су најновији резултати у развоју пероксидних антималарика. 
(Примљено 19. маја 2009) 
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